Mechanisms of aromatase inhibitor resistance

Cynthia X. Ma, Tomás Reinert, Izabela Chmielewska, Matthew J. Ellis

Research output: Contribution to journalReview articlepeer-review

256 Scopus citations


Oestrogen receptor-positive (ER +) breast cancer is a major cause of cancer death in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of recurrence, therapeutic resistance is common and essentially inevitable in advanced disease. This Review considers both genomic and cell biological explanations as to why ER + breast cancer cells persist, progress and cause an incurable, lethal, systemic disease. The design and outcomes of clinical trials are considered with the perspective that resistance mechanisms are heterogeneous, and therefore biomarker and somatic mutation-based stratification and eligibility will be essential for improvements in patient outcomes.

Original languageEnglish
Pages (from-to)261-275
Number of pages15
JournalNature Reviews Cancer
Issue number5
StatePublished - Apr 24 2015


Dive into the research topics of 'Mechanisms of aromatase inhibitor resistance'. Together they form a unique fingerprint.

Cite this